For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$1,347.11
Thesis
Eli Lilly markets the tirzepatide products Mounjaro and Zepbound, which target type 2 diabetes and obesity. As a diversified pharmaceutical company, it also advances an oral GLP-1 pipeline alongside its injectable franchise.
Catalysts
- Oral GLP-1 candidate clinical readouts
- Manufacturing capacity expansion for tirzepatide
- Label expansions for Mounjaro and Zepbound
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 18Trial initiationClinicalTrials.gov
Phase 3 trial NCT07881458 of EloraTZP in adults with obesity/overweight and type 2 diabetes begins recruiting.
- Nov 17Trial initiationClinicalTrials.gov
Phase 3 trial NCT07881432 initiated for EloraTZP in obesity without Type 2 diabetes; status NOT_YET_RECRUITING.
- Nov 17Trial initiationClinicalTrials.gov
Phase 3 trial NCT07900633 of Eloralintide (LY3841136) initiated in obesity/overweight, T2D and CV risk; status NOT_YET_RECRUITING
- Nov 12OtherClinicalTrials.gov
Phase 3 trial NCT05556512 of tirzepatide for morbidity/mortality reduction in obesity updated to ACTIVE_NOT_RECRUITING on 2026-11-12.
- Nov 9Trial readoutClinicalTrials.gov
Phase 2 trial NCT05936151 of Retatrutide on renal function in overweight/obese CKD patients completed.
- Nov 5Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial of orforglipron (LY3502970) vs dulaglutide in pediatric Type 2 diabetes (NCT07668336, recruiting)
- Nov 5Trial initiationClinicalTrials.gov
Phase 3 trial NCT07794579 of orforglipron initiated in overweight participants at risk of obesity complications.
- Nov 4Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial (NCT07369011) of Eloralintide (LY3841136) in obstructive sleep apnea with obesity or overweight; status recruiting.